

Acute Ischemic Stroke - Pipeline Insight, 2021

<https://marketpublishers.com/r/AEDABB096EC4EN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: AEDABB096EC4EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Acute Ischemic Stroke – Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Acute Ischemic Stroke Understanding

Acute Ischemic Stroke: Overview

Acute Ischemic stroke results from a sudden cessation of adequate amounts of blood reaching parts of the brain. Ischemic strokes can be divided according to territory affected or mechanism. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, the more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain. Symptoms depend on severity of the stroke and location in the brain. Some people do not experience any symptoms and others experience only one. Symptoms may include: Paralysis on one side of the body, Change in alertness, Changes in

hearing or taste, Problems swallowing, Dizziness or loss of balance, and Problems with eyesight. Treatment consists of one or a combination of two basic approaches to restore proper blood flow: 1) an injection of a clot-busting drug and 2) mechanical thrombectomy, a minimally-invasive procedure that physically removes clot from blocked arteries.

'Acute Ischemic Stroke - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines. The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Ischemic Stroke R&D. The therapies under development are focused on novel approaches to treat/improve Acute Ischemic Stroke.

Acute Ischemic Stroke Emerging Drugs Chapters

This segment of the Acute Ischemic Stroke report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Ischemic Stroke Emerging Drugs

Nerinetide: NoNO

Nerinetide (formerly NA 1) is being developed by Arbor Vita Corporation (USA) and

NoNO Inc. Nerinetide is an eicosapeptide that inhibits post-synaptic density protein 95 (PSD-95) signaling. It is believed to act as a neuroprotectant that promotes cell survival and disrupts toxic cell signals following damage to neurons. The drug is in Phase III stage of development for the treatment of patients with Acute Ischemic stroke.

Pro-UK: Tasly Pharmaceutical

Recombinant human (rh) Pro-UK, is a novel type of thrombolytic, which preferentially activates plasminogen on the fibrin surface and induces fibrin-selective clot lysis. The drug is in Phase III clinical trials in acute Ischemic stroke.

Further product details are provided in the report

Acute Ischemic Stroke: Therapeutic Assessment

This segment of the report provides insights about the different Acute Ischemic Stroke drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Ischemic Stroke

There are approx. 20+ key companies which are developing the therapies for Acute Ischemic Stroke. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. Phase III include, NoNO.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Ischemic Stroke: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Ischemic Stroke therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Ischemic Stroke drugs.

Acute Ischemic Stroke Report Insights

- Acute Ischemic Stroke Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Acute Ischemic Stroke Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Acute Ischemic Stroke drugs?

How many Acute Ischemic Stroke drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Ischemic Stroke?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Acute Ischemic Stroke and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Acute Ischemic Stroke: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Acute Ischemic Stroke – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Acute Ischemic Stroke companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Acute Ischemic Stroke Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Nerinetide: NoNO

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

SP-8203: Shin Poong Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early stage products (Phase I/II)

Comparative Analysis

JTR 161: Teijin Pharma Limited

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Acute Ischemic Stroke Key Companies

Acute Ischemic Stroke Key Products

Acute Ischemic Stroke- Unmet Needs

Acute Ischemic Stroke- Market Drivers and Barriers

Acute Ischemic Stroke- Future Perspectives and Conclusion

Acute Ischemic Stroke Analyst Views

Acute Ischemic Stroke Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Acute Ischemic Stroke

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Acute Ischemic Stroke
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Acute Ischemic Stroke - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/AEDABB096EC4EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AEDABB096EC4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970